News & Updates

Show Multimedia Only

Food processing implicated in Crohn’s disease risk

22 Oct 2022

Individuals who consume high amounts of unprocessed or minimally processed foods are less likely to develop Crohn’s disease (CD), according to a study.

22 Oct 2022

Food insecurity prevents gluten-free diet adoption in coeliac disease patients

22 Oct 2022

One in six patients with coeliac disease (CD) do not have a reliable access to a sufficient amount of affordable and nutrition food, a US study has found. This food insecurity negatively affects the adoption of a gluten-free diet (GFD) and the ability to meet recommended daily intake of most micronutrients.

22 Oct 2022

MELD-Na predicts 6-month mortality in decompensated cirrhosis patients

21 Oct 2022

A score of 28 in the Model of End-stage Liver Disease—Sodium (MELD-Na), an objective measure to identify patients with decompensated cirrhosis who are at increased risk of 6-month mortality in time-constrained settings, may prompt talks about hospice to improve value-based healthcare in these individuals, suggests a recent study.

21 Oct 2022

Tofacitinib effective in ulcerative colitis, but higher doses lead to adverse events

21 Oct 2022

The overall efficacy and safety of tofacitinib in moderate-to-severe ulcerative colitis (UC) agree with clinical trial data, but a dose-dependent increase in adverse events (AEs) occurs, which underscores the importance of early dose de-escalation, according to a study.

21 Oct 2022

Potassium competitive acid blockers go toe-to-toe with PPI in gastric acid diseases

21 Oct 2022 by

Vonoprazan, a potassium competitive acid blocker (PCAB), is better than proton pump inhibitors (PPI) for the treatment of Helicobacter pylori and erosive oesophagitis, according to a new meta-analysis.

21 Oct 2022

Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment

19 Oct 2022 by

In the phase III LEAP*-002 study, a combination regimen comprising lenvatinib and pembrolizumab appeared to have similar efficacy and safety as lenvatinib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC).

19 Oct 2022

Sugar-sweetened drink intake tied to increased IBD risk

18 Oct 2022 by

Consumption of sugar-sweetened beverages (SSBs) was associated with increased risk of inflammatory bowel disease (IBD), a large population-based study suggests. This association was not found with artificially sweetened beverages (ASBs) and natural juices.

18 Oct 2022

Vonoprazan bests PPI in erosive oesophagitis

18 Oct 2022

Treatment with vonoprazan leads to superior healing and maintenance of healing than the proton pump inhibitor (PPI) lansoprazole in patients with erosive oesophagitis, a new study has found.

18 Oct 2022